Icon (ICLR) Upgraded by BidaskClub to Sell
Icon (NASDAQ:ICLR) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.
A number of other research analysts also recently issued reports on ICLR. Mizuho set a $109.00 price target on Icon and gave the company a “hold” rating in a report on Wednesday, January 24th. SunTrust Banks restated a “buy” rating and set a $133.00 price target on shares of Icon in a report on Monday, January 22nd. Evercore ISI initiated coverage on Icon in a report on Thursday, January 18th. They set an “outperform” rating and a $126.00 price target on the stock. KeyCorp restated a “buy” rating and set a $130.00 price target on shares of Icon in a report on Thursday, January 11th. Finally, Zacks Investment Research downgraded Icon from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $124.55.
Shares of Icon (NASDAQ ICLR) opened at $107.02 on Friday. Icon has a 52 week low of $76.46 and a 52 week high of $124.48. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $5,795.35, a PE ratio of 20.54, a PEG ratio of 1.51 and a beta of 0.48.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://theolympiareport.com/2018/02/11/icon-iclr-upgraded-by-bidaskclub-to-sell.html.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.